The pregnancy case is the real one. Two randomised trials point the same way: 72% fewer affected pregnancies in the MRC trial 1, and zero neural-tube defects versus six on placebo in the second 2. When the US started fortifying flour, population rates fell about 28% 3.
The heart-and-brain case mostly collapsed. Folate reliably drops homocysteine by a quarter, so the obvious bet was fewer heart attacks and strokes. Across 37,485 patients in eight trials it did nothing for heart events, cancer, or death, only a modest stroke signal 4. The wins that survive are all in deficient people: stroke prevention where folate is scarce 5, and SSRI-resistant depression in patients who are also low on folate 6.
Which situation are you in? The right dose depends entirely on that, so find your row.
The food route works too: a cup of cooked lentils gives 358 µg, near the whole daily target, and fortified grain gets most people there without trying 9.
What you get depends on who you are. Preconception, the payoff is an outcome you never see: a pregnancy that just goes normally, months later 2. From actual deficiency, new red cells appear on the smear in three to four days and the fatigue lifts over a month or two 10. Adding L-methylfolate to a stalled SSRI, the window is eight to twelve weeks to see if you respond 6. Folate-replete and none of the above: nothing, and the aisle won't tell you that.
The fine print — when to skip it, and what people get wrong
Treating large-cell anemia or fatigue in an older adult: check B12 first. Folate fixes the blood count while the nerve damage of a B12 deficiency keeps running silent 10.
The MTHFR gene doesn't require expensive methylfolate: routine testing is advised against and ordinary intake gets carriers to normal status 11. "Start once you see two lines" is too late; the closure window has shut by then 7.
Had a colorectal polyp removed? One trial found more new adenomas on 1 mg/day folic acid, so favour the food route 12. Don't stop at the first trimester; folate stays load-bearing through pregnancy and lactation.
- 1MRC Vitamin Study Research Group (1991). Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. The Lancet. link
- 2Czeizel AE, Dudás I (1992). Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. New England Journal of Medicine. link
- 3Williams J, Mai CT, Mulinare J, et al. (2015). Updated estimates of neural tube defects prevented by mandatory folic acid fortification — United States, 1995–2011. MMWR Morbidity and Mortality Weekly Report. link
- 4Clarke R, Halsey J, Lewington S, et al. (2010). Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of Internal Medicine. link
- 5Huo Y, Li J, Qin X, et al. (2015). Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. link
- 6Papakostas GI, Shelton RC, Zajecka JM, et al. (2012). L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. American Journal of Psychiatry. link
- 7USPSTF (2023). Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. JAMA. link
- 8Wilson RD, et al. (2015). Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies. Journal of Obstetrics and Gynaecology Canada. link
- 9Bailey RL, Dodd KW, Gahche JJ, et al. (2010). Total folate and folic acid intake from foods and dietary supplements in the United States: 2003-2006. American Journal of Clinical Nutrition. link
- 10Institute of Medicine (1998). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. link
- 11Hickey SE, Curry CJ, Toriello HV (2013). ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine. link
- 12Cole BF, Baron JA, Sandler RS, et al. (2007). Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. link
დაკავშირებული სახელმძღვანელოში (8)
- — Beyond the famous pregnancy role, low folate raises homocysteine and is linked to faster hearing loss.
- — If your B12 looks low or symptoms linger, get folate checked too — the two share a pathway and one can hide trouble in the other.
- — Both are pregnancy non-negotiables — check that your prenatal covers iodine the way it covers folate.
- — Folate deficiency drives the same large-cell pattern as B12 — and the two can mask each other.
- — A positive MTHFR result almost always kicks off a methylfolate habit the evidence doesn't support — folate is the supplement actually worth knowing about.
- — Beef liver is the richest whole-food source of folate there is — one serving covers a big chunk of the day's need.
- — Iodine is half the preconception nutrition story; folate is the other half. Check both before trying to conceive.
- — B12 and folate work as a pair, and a folate dose can mask a B12 deficiency that's still damaging nerves.
Folate (Vitamin B9)
A single daily tablet with no preparation, no timing constraints, and no required behaviour change. The food-first version (leafy greens, legumes) is a dietary nudge of similar magnitude.
Lead indication has two independent rigorous RCTs showing 50–70% prevention of neural tube defects (MRC 1991, n=1,817; Czeizel & Dudás 1992, n=4,753), corroborated by population-scale fortification data across the US, Canada, Chile, and Australia (Williams et al. 2015; Crider et al. 2011). USPSTF A-recommendation (2023). Secondary indications (cardiovascular, depression, cognition) have weaker, subgroup-specific evidence — but the lead claim alone clears the multi-RCT-replicated guideline-backed bar.
In deficient individuals, repletion produces a clear reticulocyte response in 3–4 days and hemoglobin recovery over 1–2 months, resolving the fatigue/breathlessness of megaloblastic anemia (IOM 1998). For SSRI-resistant patients with low folate, adjunctive L-methylfolate at 15 mg/day produced significant HAM-D reduction over 8–12 weeks (Papakostas et al. 2012). In replete unselected populations the short-term wellness signal is near zero (Almeida et al. 2014).
Two RCTs (MRC 1991; Czeizel & Dudás 1992) plus population-scale fortification data (Williams et al. 2015) establish 50–70% prevention of neural tube defects — a categorical mortality and lifelong-disability prevention for offspring. For the adult taking it, cardiovascular trial evidence in fortified Western populations is essentially null (HOPE-2, NORVIT, VITATOPS; Clarke et al. 2010); CSPPT shows a real first-stroke reduction in folate-deficient hypertensive Chinese adults (HR 0.79). Small additive longevity effect for the adult; large reproductive-health effect at population scale.
Folate-deficiency-driven megaloblastic anemia produces fatigue and breathlessness that resolve on repletion (IOM 1998). The energy lift in folate-replete adults is not detectable in trials. Real but small across the population, concentrated in deficient and B-vitamin-comorbid subgroups.
Low folate status predicts poorer SSRI response (Bjelland et al. 2003); Coppen & Bailey 2000 showed adjunctive 0.5 mg folic acid added to fluoxetine raised response rates in women but not men. The Papakostas trials of L-methylfolate 15 mg/day as SSRI augmentation in resistant depression were positive with Cohen's d ~0.6 (Papakostas et al. 2012). Almeida's meta-analysis (n=1,073) is null in unselected populations; positive in documented deficiency or treatment resistance.
Frank folate deficiency causes pallor, glossitis, and the dermatological signature of megaloblastic anemia; repletion resolves these within weeks (IOM 1998). In folate-replete adults — the typical post-fortification Western reader — there is no measurable effect on appearance. A real but small contribution at the population level, concentrated in the deficient subgroup.
VITACOG demonstrated 29.6% slower whole-brain atrophy and preserved executive function in elderly with mild cognitive impairment and elevated homocysteine (Smith et al. 2010; de Jager et al. 2012). The effect is confined to a homocysteine-elevated subgroup and does not generalise to cognitive enhancement in unselected adults; NHANES analyses raised concern about high folic acid plus low B12 and worse cognitive test performance in seniors (Morris et al. 2010).